DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor
10 juin 2019 09h00 HE
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, June 10, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced results from a pharmacokinetic study of their novel formulation of celecoxib...